Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-cnmwb Total loading time: 0 Render date: 2024-07-16T22:43:27.414Z Has data issue: false hasContentIssue false

Chapter 23 - Cannabis and the Long-term Course of Psychosis

from Part VII - Cannabinoids and Schizophrenia: Aetiopathology and Treatment Implications

Published online by Cambridge University Press:  12 May 2023

By
Tabea Schoeler
Edited by
Deepak Cyril D'Souza ,
David Castle  and
Sir Robin Murray
Deepak Cyril D'Souza
Affiliation:
Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine
David Castle
Affiliation:
University of Tasmania, Australia
Sir Robin Murray
Affiliation:
Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
Get access

Summary

Cannabis use is highly prevalent among individuals presenting with their first episode psychosis (FEP), and a substantial proportion of individuals continue to use cannabis following the onset of the illness. Longitudinal research following up FEP patients has now started to explore in more detail the impact of cannabis use on long-term prognosis of psychosis, implicating continued cannabis use as a risk factor for an unfavourable illness course of psychosis. Since cannabis use is one factor amenable to treatment, it constitutes an attractive interventional target for early intervention. As such, a nuanced understanding of how exposure to cannabis affects the long-term course of psychosis is paramount, to help clinicians and carers to formulate the best possible treatment choices for individuals with a first episode psychosis. This chapter will focus in more detail on questions concerning the impact of cannabis use on the illness course of psychosis, including an overview of its effects on clinical and functional outcome dimensions, an assessment of causality, and a discussion on the interplay between cannabis use and other factors implicated in long-term prognosis of psychosis.

Keywords

cannabissubstance userelapseprognosis of psychosispsychiatric epidemiologyfirst episode psychosis
Type
Chapter
Information
Marijuana and Madness , pp. 240 - 245
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alvarez-Jimenez, M., Priede, A., Hetrick, S. E., et al. (2012). Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophr Res, 139, 116–128.CrossRefGoogle ScholarPubMed
Arseneault, L., Cannon, M., Witton, J., et al. (2004). Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry, 184, 110–117.Google Scholar
Bowers, M. B. (1977). Psychoses precipitated by psychotomimetic drugs: A follow-up study. Arch Gen Psychiatry, 34, 832–835.Google Scholar
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.CrossRefGoogle ScholarPubMed
Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.CrossRefGoogle ScholarPubMed
Emsley, R., Asmal, L., Rubio, J. M., et al. (2020). Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res, 225, 55–62.Google Scholar
Ferraro, L., Russo, M., O’Connor, J., et al. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res, 150, 129–135.CrossRefGoogle ScholarPubMed
Foglia, E., Schoeler, T., Klamerus, E., et al. (2017). Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analysis. Psychol Med, 47, 1691–1705.Google Scholar
Foti, D. J., Kotov, R., Guey, L. T., et al. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry, 167, 987–993.Google Scholar
Gonzalez-Pinto, A., Alberich, S., Barbeito, S., et al. (2011). Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use. Schizophr Bull, 37, 631–639.Google Scholar
Henquet, C., van Os, J., Kuepper, R., et al. (2010). Psychosis reactivity to cannabis use in daily life: An experience sampling study. Br J Psychiatry, 196, 447–453.CrossRefGoogle ScholarPubMed
Hindocha, C., Freeman, T. P., Ferris, J. A., et al. (2016). No smoke without tobacco: A global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry, 7, 104.Google Scholar
Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Rev Psychiatry, 4, 231–244.CrossRefGoogle ScholarPubMed
Korver, N., Nieman, D. H., Becker, H. E., et al. (2010). Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust NZ J Psychiatry, 44, 230–236.Google Scholar
Liem-Moolenaar, M., te Beek, E. T., de Kam, M. L., et al. (2010). Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol, 24, 1697–1708.Google Scholar
Myles, H., Myles, N., and Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiatry, 50, 208–219.Google Scholar
Ouellet-Plamondon, C., Abdel-Baki, A., Salvat, É., et al. (2017). Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychol Med, 47, 2461–2471.Google Scholar
Pelayo-Terán, J. M., Diaz, F. J., Pérez-Iglesias, R., et al. (2014). Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med, 44, 37–50.Google Scholar
Potter, D. J., Clark, P., and Brown, M. B. (2008). Potency of Δ 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forens Sci, 53, 90–94.Google Scholar
Reid, S., and Bhattacharyya, S. (2019). Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. Psychiatry Res, 280, 112523.Google Scholar
Scheffler, F., Phahladira, L., Luckhoff, H., et al. (2021). Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment. Psychiatry Res, 302, 114022.Google Scholar
Schimmelmann, B. G., Conus, P., Cotton, S., et al. (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry, 27, 463–469.Google Scholar
Schoeler, T., Kambeitz, J., Behlke, I., et al. (2016a). The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychol Med, 46, 177–188.CrossRefGoogle ScholarPubMed
Schoeler, T., Monk, A., Sami, M. B., et al. (2016b). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 3, 215–225.Google Scholar
Schoeler, T., Petros, N., Di Forti, M., et al. (2016c). Association between continued cannabis use and risk of relapse in first-episode psychosis: A quasi-experimental investigation within an observational study. JAMA Psychiatry, 73, 1173–1179.Google Scholar
Schoeler, T., Petros, N., Di Forti, M., et al. (2016d). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. Lancet Psychiatry, 3, 947–953.Google Scholar
Schoeler, T., Petros, N., Di Forti, M., et al. (2017). Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis. Psychiatry Res, 255, 36–41.Google Scholar
Setién-Suero, E., Neergaard, K., Ortiz-García de la Foz, V., et al. (2019). Stopping cannabis use benefits outcome in psychosis: Findings from 10-year follow-up study in the PAFIP-cohort. Acta Psychiatr Scand, 140, 349–359.Google Scholar
Wilson, R., and Bhattacharyya, S. (2016). Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. J Psychopharmacol, 30, 99–111.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Cannabis and the Long-term Course of Psychosis
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
  • Chapter DOI: https://doi.org/10.1017/9781108943246.024
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Cannabis and the Long-term Course of Psychosis
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
  • Chapter DOI: https://doi.org/10.1017/9781108943246.024
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Cannabis and the Long-term Course of Psychosis
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
  • Chapter DOI: https://doi.org/10.1017/9781108943246.024
Available formats
×